Vemurafenib and Dabrafenib Downregulates RIPK4 Level
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15030918
Abstract: Simple Summary RIPK4 kinase has oncogenic functions in melanoma and shows high similarity to BRAF protein, making this kinase sensitive to the BRAF inhibitors vemurafenib and dabrafenib. BRAFi downregulates RIPK4 in both BRAF-mutated and wild-type… read more here.
Keywords: braf; kinase; ripk4; downregulates ripk4 ... See more keywords
A Review on the Comparison of Vemurafenib and Dabrafenib in the treatment of Melanoma caused by Mutation of Braf
Sign Up to like & getrecommendations! Published in 2018 at "Research Journal of Pharmacy and Technology"
DOI: 10.5958/0974-360x.2018.00282.2
Abstract: Metastatic melanoma is one of the most aggressive forms of skin cancer. The mortality rate of this cancer is high .Almost 60% of the melanomas are due to the mutation of BRAF gene. BRAF V600E… read more here.
Keywords: melanoma; braf; review comparison; mutation braf ... See more keywords